The global intravenous (IV) iron drugs market size is expected to reach USD 2.90 billion by 2026, expanding at a CAGR of 7.2% during the forecast period, according to a new report by Grand View Research. Growing prevalence of chronic diseases, noncompliance of oral drug treatment and recent approvals of novel products are the key factors driving the IV iron drugs market. However, some of the factors that are restraining the market include the adverse side effects, stringent regulations, availability of nutraceutical alternatives, and complex approval process.
Iron is one of the crucial components in the hemoglobin and plays an important role in the transportation of oxygen throughout the body. It also takes part in several biological processes such as energy metabolism, formation of collagen, the synthesis of heme, formation of myoglobin, immune system functions, and neurotransmitter production. Around 30% of anemia in women and children in developing nations is caused by deficiency of iron according to a survey conducted by the Vitamin and Mineral Nutrition Information System in 2017. Growing cases of chronic kidney diseases, iron deficiency anemia in gastroenterology, gynecology and oncology and growing cohort with high rate of unresponsive oral therapy is expected to drive the demand for these drugs. Furthermore, increasing healthcare expenditure and high accuracy, sensitivity and easy access of intravenous iron drugs fuels the market growth.
Request a Free Sample Copy of Intravenous Iron Drugs Market Report @ https://www.radiantinsights.com/research/intravenous-iron-drugs-market/request-sample
\ Among the products, the ferric carboxymaltose segment dominated the global intravenous iron drugs market in 2018 and is expected to grow significantly due to its increasing application in drug discovery processes, superior performance, and reduced cost. Ferric carboxymaltose is marketed as Injectafer in North America and under the name of Ferinject outside North America. Asia Pacific is projected to demonstrate the highest CAGR during the forecast period, while North America held the largest market share in 2018.
Further key findings from the study suggest:
• Among the applications, chronic kidney disease segment held the largest IV iron drugs market share in 2018, due to increasing prevalence and geriatric population
• Ferric carboxymaltose is expected to maintain its dominance through the forecast period due to the increasing application in drug discovery, superior performance and reduced cost
• Asia Pacific is projected to exhibit the fastest growth during the forecast period, which can be attributed to the increasing prevalence of chronic diseases in the region, improving healthcare infrastructure, and rising per capita healthcare expenditure
• Key players operating in the intravenous iron drugs market include Allergan, Inc.,AMAG Pharmaceuticals. Inc.,Daiichi Sankyo Company, Ltd., Sanofi, Fresenius Medical Care AG & Co., Vifor Pharma Management Ltd., Pharmacosmos A/S, Shield Therapeutics Plc, and American Regent. Inc.
The “Intravenous Iron Drugs Market Size, Share & Trends Analysis Report” is available now at https://www.radiantinsights.com/research/intravenous-iron-drugs-market
Table of Contents
Chapter 1 Methodology and Scope
1.1 Market segmentation & scope
1.2 Market definition
1.3 Information procurement
1.4 Purchased database
1.5 GVR's internal database
1.6 Secondary sources & third party perspectives
1.7 Primary research
1.8 Information analysis
1.9 Data analysis models
1.10 Market formulation & data visualization
1.11 Data validation & publishing
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Intravenous Iron Drugs Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Framework
3.4 Market Dynamics
3.4.1 Market driver analysis
3.4.2 Market restraint analysis
3.4.3 Industry challenges
3.4.4 Industry analysis - Porter's
3.4.4.1 Supplier Power
3.4.4.2 Buyer Power
3.4.4.3 Substitution Threat
3.4.4.4 Threat from new entrants
3.4.4.5 Competitive Rivalry
3.4.5 PESTEL Analysis
3.4.5.1 Political Landscape
3.4.5.2 Environmental Landscape
3.4.5.3 Social landscape
3.4.5.4 Technology landscape
3.4.5.5 Legal Landscape
3.4.6 Major deals and strategic alliances analysis
3.4.6.1 Joint ventures
3.4.6.2 Mergers and acquisitions
3.4.6.3 Licensing and partnership
3.4.6.4 Technology collaborations
3.4.6.5 Strategic Divestments
3.4.7 Market entry strategies
To read more reports of this category, Visit our blog: https://healthandpharamceuticalri.blogspot.com
Chapter 4 Intravenous Iron Drugs Market - Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company Categorization
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis, 2018
4.4 Public Companies
4.4.1 Company market position analysis
4.4.2 Regional network map
4.4.3 Company market share, by region
4.5 Private Companies
4.5.1 List of key emerging companies
4.5.2 Company market position analysis
Chapter 5 Intravenous Iron Drugs Market: Product Estimates and Trend Analysis
5.1 Definition & Scope
5.2 Product Market Share Analysis, 2018 & 2026
5.3 Segment Dashboard
5.4 Global Intravenous Iron Drugs Market, by Product, 2015 to 2026
5.5 Market Size & Forecasts and Trend Analyses, 2015 to 2026
5.5.1 Iron Sucrose Market
5.5.1.1 Iron Sucrose Market, 2015 to 2026 (USD Million)
5.5.2 Iron Dextran Market
5.5.2.1 Iron Dextran Market, 2015 to 2026 USD Million)
5.5.3 Ferric Carboxymaltose Market
5.5.3.1 Ferric Carboxymaltose Market, 2015 to 2026 (USD Million)
5.5.4 Others Market
5.5.4.1 Others Market, 2015 to 2026 (USD Million)
